| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C B Newma. Medical therapy for acromegaly. Endocrinology and metabolism clinics of North America. vol 28. issue 1. 1999-06-10. PMID:10207690. |
both somatostatin analogues, which bind to the somatostatin receptor subtypes 2 and 5, and dopamine agonists, which are specific for the d2 receptor, have been used to treat acromegaly. |
1999-06-10 |
2023-08-12 |
Not clear |
| I Hernandez, D Soderlund, A L Espinosa-de-los-Monteros, R Ochoa, A Zarate, M Mercad. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly. Journal of neurosurgery. vol 90. issue 4. 1999-04-23. PMID:10193608. |
however, there are no studies of patients with acromegaly in which the effects of medical (that is, administration of somatostatin analogs) and surgical therapy on ghbp levels have been compared. |
1999-04-23 |
2023-08-12 |
Not clear |
| P Jaquet, I Morange-Rahos, B Janano, P Moati, T Bru. [Somatostatin agonists in the treatment of acromegaly]. Annales d'endocrinologie. vol 59. issue 4. 1999-02-10. PMID:9864550. |
[somatostatin agonists in the treatment of acromegaly]. |
1999-02-10 |
2023-08-12 |
Not clear |
| T C Chang, T J Chang, M H Chen, Y L Hsiao, K S Tsa. Effectiveness of slow-release lanreotide, a long-acting somatostatin analogue, in the treatment of acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 97. issue 10. 1999-01-05. PMID:9830278. |
effectiveness of slow-release lanreotide, a long-acting somatostatin analogue, in the treatment of acromegaly. |
1999-01-05 |
2023-08-12 |
Not clear |
| T C Chang, T J Chang, M H Chen, Y L Hsiao, K S Tsa. Effectiveness of slow-release lanreotide, a long-acting somatostatin analogue, in the treatment of acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 97. issue 10. 1999-01-05. PMID:9830278. |
we evaluated the effectiveness of slow-release lanreotide, a long-acting somatostatin analogue, in the treatment of acromegaly. |
1999-01-05 |
2023-08-12 |
Not clear |
| P M Boulou. Somatuline LA: a new treatment for acromegaly. Hospital medicine (London, England : 1998). vol 59. issue 8. 1998-12-03. PMID:9829060. |
somatostatin analogues have become well established as treatment for acromegaly. |
1998-12-03 |
2023-08-12 |
Not clear |
| U Plöckinger, A Perez-Canto, C Emde, R M Liehr, W Hopfenmüller, H J Quabb. Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly. European journal of endocrinology. vol 139. issue 4. 1998-11-30. PMID:9820614. |
effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly. |
1998-11-30 |
2023-08-12 |
Not clear |
| U Plöckinger, A Perez-Canto, C Emde, R M Liehr, W Hopfenmüller, H J Quabb. Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly. European journal of endocrinology. vol 139. issue 4. 1998-11-30. PMID:9820614. |
to study the effects of the somatostatin analog octreotide on gastric mucosal function and histology during short-term (3 months) preoperative treatment in patients with acromegaly. |
1998-11-30 |
2023-08-12 |
Not clear |
| A Colao, G Lombard. Growth-hormone and prolactin excess. Lancet (London, England). vol 352. issue 9138. 1998-11-20. PMID:9808008. |
the treatment of acromegaly and hyperprolactinaemia has been improved by the availability of effective and well-tolerated slow-release somatostatin analogues and dopamine agonists with long-lasting activity, such as cabergoline. |
1998-11-20 |
2023-08-12 |
Not clear |
| F Fallo, L Barzon, M Boscaro, E Casiglia, N Sonin. Effect of octreotide on 24-h blood pressure profile in acromegaly. American journal of hypertension. vol 11. issue 5. 1998-08-24. PMID:9633796. |
the aim of the study was to investigate the effect of octreotide, a somatostatin analog drug potentially able to inhibit growth hormone (gh), on the circadian blood pressure profile in a group of patients with acromegaly. |
1998-08-24 |
2023-08-12 |
Not clear |
| A L Barka. New options for diagnosing and treating acromegaly. Cleveland Clinic journal of medicine. vol 65. issue 7. 1998-08-13. PMID:9679389. |
in patients with acromegaly, medical treatment with a somatostatin analog normalizes growth hormone and igf-1 levels and produces clinical improvement quickly. |
1998-08-13 |
2023-08-12 |
Not clear |
| P H Davies, S E Stewart, L Lancranjan, M C Sheppard, P M Stewar. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clinical endocrinology. vol 48. issue 3. 1998-05-21. PMID:9578821. |
to evaluate the efficacy and safety of a long-acting preparation of the somatostatin analogue octreotide, sandostatin-lar (sms-lar) for the treatment of acromegaly. |
1998-05-21 |
2023-08-12 |
Not clear |
| T J Gillespie, A Erenberg, S Kim, J Dong, J E Taylor, V Hau, T P Davi. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. The Journal of pharmacology and experimental therapeutics. vol 285. issue 1. 1998-05-12. PMID:9535998. |
novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. |
1998-05-12 |
2023-08-12 |
human |
| C C Chen, F S Czerwiec, P P Feuilla. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 39. issue 2. 1998-03-12. PMID:9476926. |
somatostatin receptor scintigraphy was performed on a patient with mccune-albright syndrome and acromegaly. |
1998-03-12 |
2023-08-12 |
Not clear |
| M N Pollak, A V Schall. Mechanisms of antineoplastic action of somatostatin analogs. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). vol 217. issue 2. 1998-02-11. PMID:9452137. |
clinical efficacy and a favorable toxicity profile of somatostatin analogs in the treatment of relatively uncommon conditions such as acromegaly and neuroendocrine tumors have already been demonstrated. |
1998-02-11 |
2023-08-12 |
human |
| R Görges, U Cordes, M Engelbach, K M Bartelt, G Haberern, O Hey, J Beyer, A Bockisc. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index]. Nuklearmedizin. Nuclear medicine. vol 36. issue 4. 1997-09-09. PMID:9289697. |
the aim of our prospective study was to optimize the determination of the pituitary somatostatin receptor status by means of 111-in-pentetreotide scintigraphy and to compare it intraindividually with the pharmacological effect of octreotide in active acromegaly. |
1997-09-09 |
2023-08-12 |
Not clear |
| D Tielmans, M Assayag, M Virally-Monod, C Ajzenberg, F Gelbert, M Duet, A Warne. [Hypophyseal adenomas: functional and tumor evaluation and therapeutic approaches]. La Revue de medecine interne. vol 17. issue 11. 1997-03-07. PMID:8977971. |
pituitary function evaluation, visual acuity and field check-up, and mri or at least cat are compulsory for diagnosis, and for therapeutic approach; surgery for cushing's disease, dopamine agonists for prolactinomas, somatostatin analogs or surgery for thyrotroph adenomas, surgery and/or somatostatin analogs and/or radiotherapy in acromegaly, surgery with additional irradiation in most adenomas of other types, or even expectation in some instances. |
1997-03-07 |
2023-08-12 |
cat |
| M Gregianin, C Macrì, F Bui, L Varotto, P Zucchett. Whole body and tomographic scan with 111In-pentetreotide: preliminary data. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). vol 39. issue 4 Suppl 1. 1997-03-06. PMID:9002769. |
the patients (6 men and 5 women, age 28-68, mean 45 years) were affected by a variety of tumors which supposedly express somatostatin receptors: 2 meningotheliomatous meningiomas post-surgery; 2 glucagonomas with liver metastases observed on ct; 2 patients with suspicion of insulinoma; 2 carcinoids, one after surgery; 1 ectopic-acth cushing's syndrome; 1 intracranial germinoma, post-surgery, in whom the study was requested to evaluate a doubtful finding of pulmonary metastatic lesion on ct; and 1 acromegaly showing, on mri, and empty sella turcica occupied by and extraflexion of the lower portion of the chiasmatic cisterna without signs of adenoma and the sphenoidal sinus occupied by tissue wit inflammmatory characteristics. |
1997-03-06 |
2023-08-12 |
Not clear |
| R J Robbin. Depot somatostatin analogs--a new first line therapy for acromegaly. The Journal of clinical endocrinology and metabolism. vol 82. issue 1. 1997-01-30. PMID:8989224. |
depot somatostatin analogs--a new first line therapy for acromegaly. |
1997-01-30 |
2023-08-12 |
Not clear |
| M al-Maskari, J Gebbie, P Kendall-Taylo. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical endocrinology. vol 45. issue 4. 1997-01-02. PMID:8959079. |
the effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. |
1997-01-02 |
2023-08-12 |
Not clear |